巩固性局部消融治疗改善EGFR突变同步寡转移NSCLC一线TKI治疗患者生存
本研究纳入145例IV期EGFR突变寡转移(≤5个转移灶)NSCLC患者,均接受一线EGFR-TKI治疗,比较巩固性局部消融治疗(LAT)至全部寡转移灶、部分病灶及未行LAT的生存差异。结果显示全LAT组中位PFS和OS均显著优于部分LAT组和未LAT组,且原发灶、脑转移灶和肾上腺转移灶的巩固LAT均与OS改善相关。
要点
- 全LAT组中位PFS 20.6个月、OS 40.9个月,均显著优于部分LAT和未LAT组。
- 部分LAT与未LAT组间PFS和OS差异无统计学意义。
- 原发灶、脑转移灶和肾上腺转移灶的巩固LAT均与OS显著改善相关。
核心结论
- 对于EGFR突变寡转移NSCLC患者,一线EGFR-TKI治疗期间对全部转移灶进行巩固性LAT可显著改善PFS和OS。
研究设计与样本
- 回顾性队列研究,纳入2010年10月至2016年5月共145例IV期EGFR突变NSCLC且诊断2个月内转移灶≤5个的患者,均接受一线EGFR-TKI治疗。
主要发现
- 全LAT组(51例,35.2%)、部分LAT组(55例,37.9%)和未LAT组(39例,26.9%)的中位PFS分别为20.6、15.6和13.9个月(p < 0.001)。
- 三组中位OS分别为40.9、34.1和30.8个月(p < 0.001),全LAT组与部分LAT组或未LAT组差异显著,部分LAT组与未LAT组差异不显著。
- 原发灶巩固LAT组中位OS 40.5个月 vs 31.5个月(p < 0.001),脑转移灶LAT组38.2 vs 29.2个月(p = 0.002),肾上腺转移灶LAT组37.1 vs 29.2个月(p = 0.032)。
- 放疗相关≥3级不良事件包括肺炎(7.7%)和食管炎(16.9%)。
临床怎么用
- 对于EGFR突变寡转移NSCLC患者,一线TKI治疗期间可考虑对全部寡转移灶进行巩固性LAT以改善生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The aim of the current study was to investigate whether consolidative local ablative therapy (LAT) can improve the survival of patients with stage IV EGFR-mutant NSCLC who have oligometastatic disease treated with first-line EGFR-tyrosine kinase inhibitor (TKI) therapy. METHODS: Patients with stage IV EGFR-mutant NSCLC and no more than five metastases within 2 months of diagnosis were identified. All patients were treated with first-line EGFR-TKIs. Consolidative LAT included radiotherapy, surgery, or both. Overall survival (OS) and progression-free survival (PFS) were estimated by Kaplan-Meier curves. RESULTS: From October 2010 to May 2016, 145 patients were enrolled, including 51 (35.2%) who received consolidative LAT to all oligometastatic sites (all-LAT group), 55 (37.9%) who received consolidative LAT to either primary tumor or oligometastatic sites (part-LAT group), and 39 (26.9%) who did not receive any consolidative LAT (non-LAT group). The median PFS in all-LAT, part-LAT, and non-LAT groups were 20.6, 15.6, and 13.9 months, respectively (p < 0.001). The median OS in all-LAT, part-LAT, and non-LAT groups were 40.9, 34.1, and 30.8 months, respectively (p < 0.001). The difference was statistically significant between the all-LAT group and part-LAT or non-LAT group but was not between the part-LAT and non-LAT group. The median OS was significantly improved with consolidative LAT for primary tumor (40.5 versus 31.5 months, p < 0.001), brain metastases (38.2 versus 29.2 months, p = 0.002), and adrenal metastases (37.1 versus 29.2 months, p = 0.032). Adverse events (grade ≥ 3) due to radiotherapy included pneumonitis (7.7%) and esophagitis (16.9%). CONCLUSIONS: The current study showed that consolidative LAT to all metastatic sites was a feasible option for patients with EGFR-mutant oligometastatic NSCLC during first-line EGFR-TKI treatment, with significantly improved PFS and OS compared with consolidative LAT to partial sites or observation alone.
引用
- Xu Q, Zhou F, Liu H, et al. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs. J Thorac Oncol. 2018. PMID: 29852232. doi:10.1016/j.jtho.2018.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。